Bile acids stay high in biliary atresia patients after Kasai procedure
Bile acids, which aid the fat-digesting functions of bile fluid, remain elevated in the blood and urine of adult biliary atresia patients whose bile…
News
Canada funds projects to curb hepatitis C, blood-borne infections
Community-based organizations in Canada addressing hepatitis C, the human immunodeficiency virus (HIV), and other sexually transmitted and blood-borne infections (STBBIs) will receive more than…
FDA to review approval application for seladelpar as PBC treatment
The U.S. Food and Drug Administration (FDA) will review CymaBay Therapeutics’ application for seladelpar, an oral investigational treatment for adults with…
Algorithm for genetic tests helps spot cause of newborn cholestasis
In infants with suspected cholestasis, targeted single-gene testing for those with symptoms that indicate a particular, associated disease and broader gene panel testing for…
Tirzepatide for weight loss treats fatty liver disease in Phase 2 trial
Weekly injections of tirzepatide, an approved obesity and diabetes treatment, showed promise in people with nonalcoholic steatohepatitis (NASH) — now known as metabolic dysfunction-associated steatohepatitis…
New JAG1 mutations seen as likely cause of Alagille in 2 young boys
Researchers have identified two new mutations in JAG1, a gene linked to Alagille syndrome, that each resulted in a unique clinical profile for two…
Antiviral duo found effective for hepatitis E despite virus mutations
A combination of the antiviral medications ribavirin and sofosbuvir efficiently cleared the hepatitis E virus (HEV) from two chronically infected patients despite the emergence of…
Seladelpar lowers levels of molecule driving itch with PBC: Phase 3 trial
Seladelpar, an experimental oral therapy by CymaBay Therapeutics, significantly lowered blood levels of an itch-associated molecule called interleukin-31 (IL-31) in people with…
New study finds PFIC3 marked by increased inflammation in liver
In a wide-ranging analysis of thousands of different proteins from liver samples from transplant patients, a team of scientists in Spain discovered potential links to…
Denifanstat seen to safely treat NASH in Phase 2b clinical trial
Denifanstat, Sagimet Biosciences’ experimental therapy, outperformed a placebo at resolving nonalcoholic steatohepatitis (NASH) — a severe form of fatty liver disease —…
Recent Posts
- Abnormal amino acid profile seen in biliary atresia infants after birth
- Our daughter’s PFIC diagnosis made us rethink drinking at Christmas
- Hepatitis D treatment combo granted new designations in US, EU
- Committee recommends seladelpar approval in EU for treating PBC
- Diet rich in omega-3 fatty acids may lower risk of ICP, scientists say